CSF1R+ Macrophages Sustain Pancreatic Tumor Growth through T Cell Suppression and Maintenance of Key Gene Programs that Define the Squamous Subtype
Juliana B. Candido,
Jennifer P. Morton,
Peter Bailey,
Andrew D. Campbell,
Saadia A. Karim,
Thomas Jamieson,
Laura Lapienyte,
Aarthi Gopinathan,
William Clark,
Ewan J. McGhee,
Jun Wang,
Monica Escorcio-Correia,
Raphael Zollinger,
Rozita Roshani,
Lisa Drew,
Loveena Rishi,
Rebecca Arkell,
T.R. Jeffry Evans,
Colin Nixon,
Duncan I. Jodrell,
Robert W. Wilkinson,
Andrew V. Biankin,
Simon T. Barry,
Frances R. Balkwill,
Owen J. Sansom
Affiliations
Juliana B. Candido
Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK
Jennifer P. Morton
Cancer Research UK Beatson Institute, Glasgow G61 1BD, UK; Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1QH, UK
Peter Bailey
Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1QH, UK
Andrew D. Campbell
Cancer Research UK Beatson Institute, Glasgow G61 1BD, UK
Saadia A. Karim
Cancer Research UK Beatson Institute, Glasgow G61 1BD, UK
Thomas Jamieson
Cancer Research UK Beatson Institute, Glasgow G61 1BD, UK
Laura Lapienyte
Cancer Research UK Beatson Institute, Glasgow G61 1BD, UK
Aarthi Gopinathan
Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK
William Clark
Cancer Research UK Beatson Institute, Glasgow G61 1BD, UK
Ewan J. McGhee
Cancer Research UK Beatson Institute, Glasgow G61 1BD, UK
Jun Wang
Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK
Monica Escorcio-Correia
Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK
Raphael Zollinger
Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK
Rozita Roshani
Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK
Lisa Drew
Bioscience, Oncology, iMED Biotech Unit, AstraZeneca, Boston, MA, USA
Loveena Rishi
Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1QH, UK
Rebecca Arkell
Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK
T.R. Jeffry Evans
Cancer Research UK Beatson Institute, Glasgow G61 1BD, UK; Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1QH, UK
Colin Nixon
Cancer Research UK Beatson Institute, Glasgow G61 1BD, UK
Duncan I. Jodrell
Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK
Robert W. Wilkinson
MedImmune Ltd, Granta Park, Cambridge CB21 6GH, UK
Andrew V. Biankin
Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1QH, UK
Simon T. Barry
Bioscience, Oncology, iMED Biotech Unit, AstraZeneca, Cambridge, UK
Frances R. Balkwill
Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK
Owen J. Sansom
Cancer Research UK Beatson Institute, Glasgow G61 1BD, UK; Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1QH, UK; Corresponding author
Summary: Pancreatic ductal adenocarcinoma (PDAC) is resistant to most therapies including single-agent immunotherapy and has a dense desmoplastic stroma, and most patients present with advanced metastatic disease. We reveal that macrophages are the dominant leukocyte population both in human PDAC stroma and autochthonous models, with an important functional contribution to the squamous subtype of human PDAC. We targeted macrophages in a genetic PDAC model using AZD7507, a potent selective inhibitor of CSF1R. AZD7507 caused shrinkage of established tumors and increased mouse survival in this difficult-to-treat model. Malignant cell proliferation diminished, with increased cell death and an enhanced T cell immune response. Loss of macrophages rewired other features of the TME, with global changes in gene expression akin to switching PDAC subtypes. These changes were markedly different to those elicited when neutrophils were targeted via CXCR2. These results suggest targeting the myeloid cell axis may be particularly efficacious in PDAC, especially with CSF1R inhibitors. : Candido et al. find that CSF-1R+ macrophages play a vital role in pancreatic tumor maintenance, suppression of T cells, and tumor gene networks based on transcriptome analysis. In an autochthonous model, CSF-1R inhibition alters the gene expression programs that influence subtype specification of PDAC and extends survival. Keywords: pancreatic cancer, macrophages, CSF1R, T cells